Showing 181-190 of 7165 results for "".
How to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.How Health Care Worker Dissatisfaction is Fueling a New Trend in Health Care
https://practicaldermatology.com/topics/practice-management/how-health-care-worker-dissatisfaction-is-fueling-a-new-trend-in-health-care/23837/Despite strain, many health care workers are finding new opportunities.DEI in Dermatology
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/dei-in-dermatology/20143/Dermatology remains one of the least diverse medical specialties, says Jeanine Downie, MD. There have been small steps forward to improve diversity, equity, inclusion, and accessibility in recent years, such as the DREAM initiative from Allergan Aesthetics and skinbetter science. But there is stillDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)Estrogen and Skin: What Can We Do
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/estrogen-and-skin-what-can-we-do/20123/There’s accumulated evidence that depletion of estrogen with age contributes to the visible signs of skin aging. But dermatologists haven’t had many treatment options—until now. Joel L. Cohen, MD addresses the latest developments in care for estrogen deficient skin.The Roots of Dermatology
https://practicaldermatology.com/topics/practice-management/the-roots-of-dermatology/18355/The roots of dermatology run deep. The specialty formed in Europe, but Americans soon took a leading role in shaping the future of the field. This first of four episodes explores the early days of the specialty and takes stock of dermatology today.Clinical Conversations: MOA of JAK Inhibitors in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology/20096/JAK inhibitors have a range of potential applications in clinical dermatology. In the first video of this series, Brad Glick, DO and Raj Chovatiya, MD explain the mechanism of action of JAK inhibitors and explain how they may be used topically or systemically to treat skin diseases like atopic dermaDermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesDermWireTV: Staff Vaccinations, Dupilumab Data, Rosacea Resource, Sensitive Skin Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-staff-vaccinations-dupilumab-data-rosacea-resource-sensitive-skin-week/19907/Most physicians have had a chance to be vaccinated, but staff may be a different story. Some practices are struggling with policies for mandated staff vaccines. The National Rosacea Society has updated its most popular educational booklet, “Understanding Rosacea.” New data highlight the potential im